Edity Therapeutics
Using Human Immune Cells to Deliver Therapeutic Proteins
Company Overview
Snapshot
Founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster, Edity Therapeutics operates with 11–50 employees. The company has raised $13.63 million across three funding rounds from seven investors. In January 2024, Edity Therapeutics entered a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach.
Business overview
Edity Therapeutics is developing a platform that leverages the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells. This technology aims to reprogram cells and tissue to restore health by changing the course of disease at the intracellular level through mechanisms such as protein replacement, target modulation, genetic correction, and protein gain of function. The company is currently focused on indications within oncology and genetic disease, with additional programs in development for regeneration and longevity, operating within the Health Tech & Life Sciences sector.
Strategic signal
In January 2024, Edity Therapeutics announced a strategic collaboration with Dr. Reddy's Laboratories to advance its proprietary delivery platform for novel cell therapy. This partnership provides significant validation for Edity's technology and signals a strong move towards commercialization and broader market reach, potentially accelerating the development and application of its immune cell-harnessing therapeutic protein delivery system.
Log in to access full profile ›Company Intelligence Q&A
- What is Edity Therapeutics' core technology?
- Edity Therapeutics is developing a platform that harnesses the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells, aiming to reprogram cells and tissue back to health.
- When was Edity Therapeutics founded and by whom?
- Edity Therapeutics was founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster.
- What significant partnership did Edity Therapeutics announce?
- In January 2024, Edity Therapeutics entered into a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach using its proprietary delivery platform.
- Which investors participated in Edity Therapeutics' October 2023 funding round?
- In October 2023, Edity Therapeutics received funding from investors including OurCrowd.
- What is the primary focus of Edity Therapeutics' therapeutic programs?
- Edity Therapeutics is currently working across various indications, including oncology and genetic disease, while also developing programs for regeneration and longevity.